Biotech Archives - Page 83 of 795

2 minute read

Why Is Vanda Pharmaceuticals Stock Trading Higher Today?

April 3, 8:48 AM

FDA approves Vanda Pharmaceuticals' Fanapt tablets for bipolar I disorder manic or mixed episodes in adults. Fanapt, an atypical antipsychotic, shows significant improvement over placebo in pivotal study.

VNDA

2 minute read

Nanobiotix Announces Completion Of Phase 1 Dose Escalation And NBTXR3 Recommended Phase 2 Dose For The Treatment Of Inoperable, Recurrent Lung Cancer In Patients Amenable To Re-Irradiation

By Benzinga Newsdesk

April 2, 4:17 PM

Established recommended Phase 2 dose of NBTXR3 for the treatment of patients with inoperable, recurrent non-small cell lung cancer ("NSCLC") who have previously received definitive radiation therapyConfirmation of

NBTX

2 minute read

Cal-Maine Foods, Inc. Reports Positive Test Result For Avian Influenza At Texas Facility, Resulting In Depopulation Of ~1.6M Laying Hens And 337,000 Pullets, Or ~3.6% Of The Company’s Total Flock As Of March 2, 2024

By Benzinga Newsdesk

April 2, 4:14 PM

Cal-Maine Foods, Inc. (NASDAQ:CALM) ("Cal-Maine Foods" or "Company") today reported that one of the Company's facilities located in Parmer County, Texas, tested positive for highly pathogenic avian influenza ("HPAI"),

CALM

3 minute read

Sight Sciences Announces The Results Of The 3-Year Prospective GEMINI Trial And The Cross-Over Phase Of The SAHARA RCT At The 2024 American Society Of Cataract And Refractive Surgery Annual Meeting

By Benzinga Newsdesk

April 2, 4:13 PM

Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of TearCare® technology as a primary treatment for dry eye disease. MENLO PARK,

SGHT

2 minute read

Zentalis Pharmaceuticals To Highlight Preclinical Data Demonstrating That WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity With KRAS(G12C) Inhibitors At AACR Annual Meeting 2024

By Benzinga Newsdesk

April 2, 4:07 PM

Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of

ZNTL

1 minute read

LENZ Therapeutics To Host Investor Call To Discuss Topline Results From The Phase 3 CLARITY Presbyopia Trials On Wednesday, April 3, 2024, At 8:00 a.m. EST

By Benzinga Newsdesk

April 2, 4:03 PM

Conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. EST

LEN

2 minute read

Biden Government Again Missed Menthol Cigarettes Ban Deadline, Lawsuit Challenges FDA’s Delay

By Vandana Singh

April 2, 2:56 PM

Facing delays, the FDA's proposal to ban menthol cigarettes in the US encounters setbacks as White House officials miss yet another deadline. Industry giants like Altria and British American Tobacco face uncertainty as calls to enforce the ban intensify.

BTI

2 minute read

AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race

By Vandana Singh

April 2, 2:54 PM

AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over future growth. Soriot's strategic overhaul focuses on R&D and acquisitions.

AZN

2 minute read

Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand

By Vandana Singh

April 2, 2:41 PM

Citi Research raises price target for Eli Lilly, citing improved risk-adjusted sales outlook for GLP-1 agonist orforglipron. With Phase 3 trials ongoing since 2023, concerns about liver toxicity diminish. Analysts foresee potential sales surpassing $85 billion, closely watching competitive landscape.

LLY

2 minute read

What’s Going With COVID-19 Test Maker QuidelOrtho Stock On Tuesday?

By Vandana Singh

April 2, 1:05 PM

QuidelOrtho secures FDA approval for QuickVue COVID-19 test, catering to home and medical settings. Despite Savanna RVP4+ assay withdrawal, company promises a new multiplex assay for 2024/2025 respiratory season.

QDEL